About 75% of persons with hemophilia live in the developing world and do not have access
to routine care due to many barriers. There are a lot of challenges associated with …

Industrial plasma fractionation, a complex and highly regulated technology, remains largely
inaccessible to many low‐and middle‐income countries (LMICs). This, combined with the …

Over recent decades, management of people with hemophilia (PwH) has been greatly
improved by scientific advances that have resulted in a rich and varied therapeutic …

The prospect of hemophilia patients has dramatically improved in the last few decades with
the introduction of various interventions that can effectively treat or prevent their bleeding …

The spectrum of hematological diseases in African children includes anemias, bleeding
disorders, thromboses, and oncological diseases such as leukemias. While data are limited …

Clinical guidelines and expert groups recommend the use of pharmacokinetic (PK)-guided
dosing of factor replacement therapy for the treatment of bleeding disorders, especially for …

Objective This study aimed to measure the cost-effectiveness of prophylaxis with
emicizumab in PsHAhri on ITI in Brazil. Methods A cost-effectiveness modeling analysis was …

Costs of hemophilia A treatment are increasing. Waste of clotting products should be
avoided. To estimate the first-year waste of emicizumab prophylaxis for people with …

Introduction Haemophilia B is a debilitating hereditary coagulation disorder characterized by
prolonged or spontaneous episodes of bleeding caused by a deficiency of endogenous …

Hemophilia A (HA) is a genetic disorder of hemostasis associated with a deficiency or
reduced activity of clotting factor VIII (FVIII). This disorder remains unacceptably …